Nasopharyngeal carriage of Streptococcus pneumoniae in Latin America and the Caribbean: A systematic review and meta-analysis. by Martín Brizuela, María Carolina Palermo, Tomás Alconada, María Macarena Sandoval, Eugenia Ramirez Wierzbicki, Joaquín Cantos, Paula Gagetti, Agustín Ciapponi, Ariel Bardach, Silvina Ruvinsky

“…<h4>Background</h4>Streptococcus pneumoniae is a leading cause of morbidity and mortality globally, causing bacteremic pneumonia, meningitis, sepsis, and other invasive pneumococcal diseases. Evidence supports nasopharyngeal pneumococcal carriage as a reservoir for transmission and precursor of pneumococcal disease.…”
Get full text

Impact of COVID-19 on testing, positive cases, patient characteristics, and hospital contacts for respiratory syncytial virus, influenza, and pneumococcus in Danish children by Andreas Jensen, Lone Graff Stensballe

“…This comprehensive study investigates the impact of these interventions on the incidence of respiratory syncytial virus, influenza, and invasive pneumococcal disease in Danish children. Methods: We conducted a descriptive study based on a cohort of 1,790,464 Danish children from 2012 to 2022. …”
Get full text

Immunisation schedule of the Pediatric Spanish Association: 2024 recommendations by Francisco José Álvarez García, Antonio Iofrío de Arce, Javier Álvarez Aldeán, Elisa Garrote Llanos, Lucía López Granados, María Luisa Navarro Gómez, Valentín Pineda Solas, Irene Rivero Calle, Jesús Ruiz-Contreras, Ignacio Salamanca de la Cueva, Pepe Serrano Marchuet, Francisco José Álvarez García, Antonio Iofrío de Arce, Javier Álvarez Aldeán, María Garcés-Sánchez, Elisa Garrote Llanos, Abián Montesdeoca Melián, María Luisa Navarro Gómez, Valentín Pineda Solas, Irene Rivero Calle, Jesús Ruiz-Contreras, Pepe Serrano Marchuet

“…The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties:Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age.As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age.Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10–12 years of age.To complete protection against meningococcal disease in adolescence, we recommend vaccination against MenB at age 12 years.We believe that vaccination against seasonal influenza should be routine up to age 18 years, but given the disappointing coverage in children aged 6–59 months, we currently consider that improving this coverage should be prioritised, extending vaccination to children and adolescents aged 5–18 years once this objective has been achieved.Among other aspects, the routine immunization tables for healthy individuals and risk groups, the use of the new extended-valence conjugate vaccines against pneumococcal disease, routine vaccination at 4 months of age with MenACWY and vaccination against SARS-CoV-2 for individuals aged more than 6 months with risk factors remain unchanged with respect to the 2024 schedule. …”
Get full text

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children by Susanna Esposito, Nicola Principi

“…We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.…”
Get full text

Effect of Hemoadsorption for Cytokine Removal in Pneumococcal and Meningococcal Sepsis by Francesca Leonardis, Viviana De Angelis, Francesca Frisardi, Chiara Pietrafitta, Ivano Riva, Tino Martino Valetti, Valentina Broletti, Gianmariano Marchesi, Lorenza Menato, Roberto Nani, Franco Marson, Mirca Fabbris, Luca Cabrini, Sergio Colombo, Alberto Zangrillo, Carlo Coniglio, Giovanni Gordini, Lucia Stalteri, Giovanni Giuliani, Vittorio Dalmastri, Gaetano La Manna

“…From this first experience, extracorporeal cytokine removal seems to be a valid and safe therapy in the management of meningococcal and pneumococcal diseases and may contribute to the patient stabilization and prevention of severe sequelae. …”
Get full text